Outcomes of Therapy with Venetoclax Combined with Hypomethylating Agents in Favorable-Risk Acute Myeloid Leukemia (AML)

被引：2
|
作者：
Arslan, Shukaib
Zhang, Jianying
Dhakal, Prajwal
Moran, Jenna A.
Naidoo, Nuthana
Story, Jennifer Lombardi
Pullarkat, Vinod A.
Stein, Anthony S.
Marcucci, Guido
Yaghmour, George
Bhatt, Vijaya R.
Fathi, Amir T.
Aldoss, Ibrahim
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-142780
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Impact of AML1/ETO Fusion on the Efficacy of Venetoclax Plus Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia
    Jin, Dian
    Chen, Haoguang
    He, Jingsong
    Li, Yi
    Zheng, Gaofeng
    Yang, Yang
    Zhao, Yi
    Le, Jing
    Shu, Wenxiu
    He, Donghua
    Cai, Zhen
    TARGETED ONCOLOGY, 2024, 19 (02) : 237 - 249
  • [42] Intensified-Dose Chemotherapy in Combination With Gemtuzumab-Ozogamicin for the Treatment of Favorable-Risk Acute Myeloid Leukemia (AML)
    Vegunta, Rathnamitreyee
    Harel, Ronen
    Steinberg, Amir
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (06)
  • [43] Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia
    Xu, Xuezhu
    Liu, Rui
    He, Aili
    Wang, Fangxia
    HEMATOLOGY, 2023, 28 (01)
  • [44] Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia
    Strickland, Stephen A.
    Shaver, Aaron C.
    Byrne, Michael
    Daber, Robert D.
    Ferrell, P. Brent
    Head, David R.
    Mohan, Sanjay R.
    Mosse, Claudio A.
    Moyo, Tamara K.
    Stricker, Thomas P.
    Vnencak-Jones, Cindy
    Savona, Michael R.
    Seegmiller, Adam C.
    LEUKEMIA RESEARCH, 2018, 65 : 67 - 73
  • [45] Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax
    Asghari, Hannah
    Lee, Dasom
    Deutsch, Yehuda E.
    Chan, Onyee
    Al Ali, Najla
    Boisclair, Stephanie
    Brahim, Amanda
    Padron, Eric
    Kuykendall, Andrew T.
    List, Alan F.
    Fernandez, Hugo F.
    Lancet, Jeffrey E.
    Sallman, David A.
    Komrokji, Rami S.
    Sweet, Kendra L.
    Talati, Chetasi
    BLOOD, 2019, 134
  • [46] Outcomes of Acute Myeloid Leukemia Treated with a Hypomethylating Agent and Venetoclax: A Single Institution Analysis
    Zimmer, Markie
    Jacob, Brigid
    Spica, Mikayla
    Ghosh, Sunita
    Dabak, Vrushali S.
    BLOOD, 2024, 144 : 6040 - 6041
  • [47] ELN 2022 Favorable Genetic Risk Acute Myeloid Leukemia Treated with Venetoclax Plus Hypomethylating Agent: Predictors of Response and Survival
    McCullough, Kristen
    Karrar, Omer
    Iftikhar, Moazah
    Abdelmagid, Maymona
    Al-Kali, Aref
    Alkhateeb, Hassan
    Begna, Kebede
    Mangaonkar, Abhishek A.
    Saliba, Antoine
    Hefazi, Mehrdad
    Litzow, Mark R.
    Hogan, William J.
    Shah, Mithun V.
    Patnaik, Mrinal M.
    Pardanani, Animesh D.
    Tefferi, Ayalew
    Gangat, Naseema
    BLOOD, 2023, 142
  • [48] Utilization of Hypomethylating Agents and Associated Outcomes in Elderly Acute Myeloid Leukemia (AML) Patients: A Population Based Study
    Mehra, Maneesha
    He, Jimmy
    Potluri, Ravi
    Loefgren, Christina
    BLOOD, 2017, 130
  • [49] Heterogeneous Definitions of Secondary Acute Myeloid Leukemia (AML) Yield Distinct Outcomes in Response to First-Line Treatment with Hypomethylating Agents (HMA) and Venetoclax (Ven)
    Tan, Irena
    Schwede, Matthew
    Phan, Paul
    Yin, Raymond
    Zhang, Tian Y.
    Mannis, Gabriel N.
    BLOOD, 2021, 138
  • [50] Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
    Tenold, Matthew E.
    Moskoff, Benjamin N.
    Benjamin, David J.
    Hoeg, Rasmus T.
    Rosenberg, Aaron S.
    Abedi, Mehrdad
    Tuscano, Joseph M.
    Jonas, Brian A.
    FRONTIERS IN ONCOLOGY, 2021, 11
12345